This program is incredibly difficult to get access to and has been monopolized by a few elite institutions whose name recognition potential seems to have blinded funders. These institutions basically control everything about the cohort, but they're not innovating well with the data that's available and I haven't seen much of anything interesting coming out of the investment. This is in stark contrast to the UK Biobank which has access control but is relatively egalitarian in access. It's been producing major results since just a few years after it's inception, and continues to.
